Evidence map›Paper›PMID 31058073›Full record

ArticleFrontiers in oncology2019

Non-coding and Coding Transcriptional Profiles Are Significantly Altered in Pediatric Retinoblastoma Tumors.

Swetha Rajasekaran, Lakshmi Dhevi Nagarajha Selvan, Kathleen Dotts, Ranjith Kumar, Pukhraj Rishi, Vikas Khetan, Madhoolika Bisht, Karthikeyan Sivaraman, Subrmanian Krishnakumar, Debashis Sahoo and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. ChromogenicNon-coding RNA research · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.Annals of oncology : official journal of the European Society for Medical Oncology · 2022
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Swetha RajasekaranDepartment of Molecular Genetics, The Ohio State University, Columbus, OH, United States.
Lakshmi Dhevi Nagarajha SelvanDepartment of Nanobiotechnology, Vision Research Foundation, Sankara Nethralaya, Chennai, India.
Kathleen DottsDepartment of Molecular Genetics, The Ohio State University, Columbus, OH, United States.
Ranjith KumarDepartment of Nanobiotechnology, Vision Research Foundation, Sankara Nethralaya, Chennai, India.
Pukhraj RishiShri Bhagwan Mahavir Vitreoretinal Services and Ocular Oncology Services, Medical Research Foundation, Sankara Nethralaya, Chennai, India.
Vikas KhetanShri Bhagwan Mahavir Vitreoretinal Services and Ocular Oncology Services, Medical Research Foundation, Sankara Nethralaya, Chennai, India.
Madhoolika BishtDepartment of Molecular Genetics, The Ohio State University, Columbus, OH, United States.
Karthikeyan SivaramanMedGenome, Bangalore, India.
Subrmanian KrishnakumarL&T Department of Ocular Pathology, Vision Research Foundation, Chennai, India.
Debashis SahooDepartment of Pediatrics and Department of Computer Science and Engineering, University of California, San Diego, San Diego, CA, United States.
Moray J CampbellDivision of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, United States.
Sailaja V ElchuriDepartment of Nanobiotechnology, Vision Research Foundation, Sankara Nethralaya, Chennai, India.
Wayne O MilesDepartment of Molecular Genetics, The Ohio State University, Columbus, OH, United States.
Sankara Nethralaya · INThe Ohio State University · USOil and Natural Gas Corporation (India) · INSciGenom Labs (India) · INUniversity of California, San Diego · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Interplay between transcription and translationK22CA204352 · NCI · OHIO STATE UNIVERSITY · PI MILES, WAYNE · 2016 to 2018
$561k
NCI NIH HHS K22 CA204352NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

Retinoblastoma is a rare pediatric tumor of the retina, caused by the homozygous loss of the Retinoblastoma 1 (RB1) tumor suppressor gene. Previous microarray studies have identified changes in the expression profiles of coding genes; however, our understanding of how non-coding genes change in this tumor is absent. This is an important area of research, as in many adult malignancies, non-coding genes including LNC-RNAs are used as biomarkers to predict outcome and/or relapse. To establish a complete and in-depth RNA profile, of both coding and non-coding genes, in Retinoblastoma tumors, we conducted RNA-seq from a cohort of tumors and normal retina controls. This analysis identified widespread transcriptional changes in the levels of both coding and non-coding genes. Unexpectedly, we also found rare RNA fusion products resulting from genomic alterations, specific to Retinoblastoma tumor samples. We then determined whether these gene expression changes, of both coding and non-coding genes, were also found in a completely independent Retinoblastoma cohort. Using our dataset, we then profiled the potential effects of deregulated LNC-RNAs on the expression of neighboring genes, the entire genome, and on mRNAs that contain a putative area of homology. This analysis showed that most deregulated LNC-RNAs do not act locally to change the transcriptional environment, but potentially function to modulate genes at distant sites. From this analysis, we selected a strongly down-regulated LNC-RNA in Retinoblastoma, DRAIC, and found that restoring DRAIC RNA levels significantly slowed the growth of the Y79 Retinoblastoma cell line. Collectively, our work has generated the first non-coding RNA profile of Retinoblastoma tumors and has found that these tumors show widespread transcriptional deregulation.

Indexed as

DRAICLNC-RNAsLNC targetingretinoblastomaRNA-sequencing

Identifiers

PMID31058073
PMCPMC6477087
OpenAlexW2939309890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.